-
公开(公告)号：US08067011B2
公开(公告)日：2011-11-29
申请号：US11697945
申请日：2007-04-09
申请人： Claude Geoffrey Davis , Miguel A. de los Rios , Kenneth J. Oh , Timothy L. Bullock , Patrick T. Johnson , Jacek Ostrowski
发明人： Claude Geoffrey Davis , Miguel A. de los Rios , Kenneth J. Oh , Timothy L. Bullock , Patrick T. Johnson , Jacek Ostrowski
IPC分类号： A61K39/29 , A61K39/385 , C07K14/02
CPC分类号： A61K9/1272 , A61K9/5184 , A61K47/6849 , A61K47/6913 , A61K51/1234 , A61K2039/505 , A61K2039/5258 , C07K16/2803 , C07K16/3061 , C07K2317/77 , Y10S977/795 , Y10S977/797 , Y10S977/798 , Y10S977/80 , Y10S977/801 , Y10S977/802
摘要： The present invention provides a targeted multi-layered drug delivery system for the delivery of cytotoxic agents to B-cells.
摘要翻译： 本发明提供了用于将细胞毒性剂递送至B细胞的靶向多层药物递送系统。
-
公开(公告)号：US20140010885A1
公开(公告)日：2014-01-09
申请号：US13353222
申请日：2012-01-18
CPC分类号： A61K9/5169 , A61K9/5089 , A61K9/5184 , A61K47/6901 , A61K47/6925 , B82Y5/00 , C07K14/005 , C12N15/88 , C12N2730/10122
摘要： A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the bioactive agent, a lipid layer or lipid/cholesterol layer coat and targeting or facilitating molecules anchored in the lipid layer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided.
摘要翻译： 提供了用于递送各种生物活性剂（包括肽，蛋白质，核酸或合成化学药物）的自组装纳米颗粒药物递送系统。 本文所述的自组装纳米颗粒药物递送系统包括病毒衣壳蛋白，例如包封生物活性剂的乙型肝炎病毒核心蛋白，脂质层或脂质/胆固醇层包衣，并靶向或促进锚定在脂质层中的分子。 还提供了用于构建自组装纳米颗粒药物递送系统的方法。
-
3.发明申请CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME 审中-公开CHIMERIC THERAPEUTICS，组合物和使用方法公开(公告)号：US20110293726A1
公开(公告)日：2011-12-01
申请号：US13083132
申请日：2011-04-08
申请人： Miguel de los Rios , John Mendlein , Timothy L. Bullock , Kenneth J. Oh , Patrick T. Johnson , Jacek Ostrowski , Stephanie de los Rios
发明人： Miguel de los Rios , John Mendlein , Timothy L. Bullock , Kenneth J. Oh , Patrick T. Johnson , Jacek Ostrowski , Stephanie de los Rios
IPC分类号： A61K9/14 , C07K14/02 , A61K38/16 , A61P9/10 , A61P35/02 , A61P27/02 , A61P27/10 , A61P27/06 , C07K14/005 , A61P35/00
CPC分类号： A61K48/0041 , A61K38/00 , C07K14/005 , C07K2319/21 , C07K2319/80 , C12N15/88 , C12N2730/10122
摘要： Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosed chimeric therapeutics.
摘要翻译： 公开了嵌合治疗剂，其包括修饰的病毒核心蛋白质和与修饰的病毒核心蛋白质结合的核酸。 核酸可以与特定基因靶基本上同源。 在一些实施方案中，与经修饰的病毒核心蛋白结合的核酸基本上是非免疫原性的。 还公开了包括公开的嵌合治疗剂的颗粒和组合物。
-
4.发明申请CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME 审中-公开CHIMERIC THERAPEUTICS，组合物和使用方法公开(公告)号：US20110293727A1
公开(公告)日：2011-12-01
申请号：US13083226
申请日：2011-04-08
申请人： Miguel de los Rios , John Mendlein , Timothy L. Bullock , Kenneth J. Oh , Patrick T. Johnson , Jacek Ostrowski , Stephanie de los Rios
发明人： Miguel de los Rios , John Mendlein , Timothy L. Bullock , Kenneth J. Oh , Patrick T. Johnson , Jacek Ostrowski , Stephanie de los Rios
IPC分类号： A61K9/14 , C07K14/02 , A61K38/16 , A61P11/00 , A61P17/06 , A61P29/00 , A61P31/18 , A61P31/14 , A61P11/06 , A61P11/08 , A61P9/10 , A61P37/06 , A61P1/16 , A61P35/00 , A61P17/00 , A61P11/02 , A61P37/08 , C07K14/005
CPC分类号： A61K31/7105 , A61K38/00 , A61K47/62 , A61K47/6901 , A61K47/6921 , B82Y5/00 , C07K14/005 , C12N15/111 , C12N15/113 , C12N2310/3513 , C12N2320/32 , C12N2730/10122
摘要： Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosec chimeric therapeutics.
摘要翻译： 公开了嵌合治疗剂，其包括修饰的病毒核心蛋白质和与修饰的病毒核心蛋白质结合的核酸。 核酸可以与特定基因靶基本上同源。 在一些实施方案中，与经修饰的病毒核心蛋白结合的核酸基本上是非免疫原性的。 还公开了包括公开嵌合治疗剂的颗粒和组合物。
-
公开(公告)号：US20110293725A1
公开(公告)日：2011-12-01
申请号：US13083069
申请日：2011-04-08
申请人： Miguel de los Rios , John Mendlein , Timothy L. Bullock , Kenneth J. Oh , Patrick T. Johnson , Jacek Ostrowski , Stephanie de los Rios
发明人： Miguel de los Rios , John Mendlein , Timothy L. Bullock , Kenneth J. Oh , Patrick T. Johnson , Jacek Ostrowski , Stephanie de los Rios
IPC分类号： A61K9/14 , C07K14/02 , A61K38/16 , A61P9/10 , A61P3/10 , A61P19/02 , A61P9/04 , A61P7/02 , A61P3/04 , A61P19/10 , A61P25/00 , A61P35/00 , C07K14/005 , A61P9/00
CPC分类号： C12N15/88 , A61K47/6911 , A61K47/6913 , A61K48/0041 , C07K14/005 , C07K2319/21 , C07K2319/80 , C12N2730/10122
摘要： Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosec chimeric therapeutics.
-
公开(公告)号：US20090226525A1
公开(公告)日：2009-09-10
申请号：US12082154
申请日：2008-04-09
CPC分类号： A61K9/5169 , A61K9/5089 , A61K9/5184 , A61K47/6901 , A61K47/6925 , B82Y5/00 , C07K14/005 , C12N15/88 , C12N2730/10122
摘要： A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the bioactive agent, a lipid layer or lipid/cholesterol layer coat and targeting or facilitating molecules anchored in the lipid layer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided.
摘要翻译： 提供了用于递送各种生物活性剂（包括肽，蛋白质，核酸或合成化学药物）的自组装纳米颗粒药物递送系统。 本文所述的自组装纳米颗粒药物递送系统包括病毒衣壳蛋白，例如包封生物活性剂的乙型肝炎病毒核心蛋白，脂质层或脂质/胆固醇层包衣，并靶向或促进锚定在脂质层中的分子。 还提供了用于构建自组装纳米颗粒药物递送系统的方法。
-
公开(公告)号：US20170119689A1
公开(公告)日：2017-05-04
申请号：US15183167
申请日：2016-06-15
CPC分类号： A61K9/5184 , A61K9/1277 , A61K9/5192 , A61K47/6901 , A61K47/6913 , B82Y5/00 , C07K14/005 , C07K2319/00 , C12N7/00 , C12N2730/10122 , C12N2730/10123 , Y10S977/795 , Y10S977/797 , Y10S977/798 , Y10S977/80 , Y10S977/801 , Y10S977/802
摘要： A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided.
-
公开(公告)号：US20110293733A1
公开(公告)日：2011-12-01
申请号：US13085892
申请日：2011-04-13
IPC分类号： A61K9/14 , A61K31/711 , A61K39/395 , A61K31/7105 , A61P9/00 , A61P11/00 , A61P25/00 , A61P25/04 , A61P11/06 , A61P31/00 , A61P25/24 , A61P3/10 , A61P31/10 , A61P9/12 , A61P29/00 , A61P35/00 , A61P25/22 , A61P37/06 , A61P37/02 , A61P25/06 , A61P25/20 , A61P9/10 , A61P25/18 , A61P9/06 , A61P19/02 , A61P19/06 , A61P7/02 , A61P7/04 , A61P7/00 , A61P25/08 , A61P25/16 , A61P17/04 , A61P31/04 , A61P31/12 , A61P11/08 , A61P3/08 , A61P3/06 , A61P1/04 , A61P1/08 , A61P3/02 , A61K38/02
CPC分类号： A61K9/5184 , A61K9/1277 , A61K9/5192 , A61K47/6901 , A61K47/6913 , B82Y5/00 , C07K14/005 , C07K2319/00 , C12N7/00 , C12N2730/10122 , C12N2730/10123 , Y10S977/795 , Y10S977/797 , Y10S977/798 , Y10S977/80 , Y10S977/801 , Y10S977/802
摘要： A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided.
摘要翻译： 提供了用于递送药物的自组装纳米颗粒药物递送系统，包括肽，蛋白质，核酸或合成化学药物。 本文所述的自组装纳米颗粒药物递送系统包括病毒衣壳蛋白，例如包封药物的乙型肝炎病毒核心蛋白，脂质双层包膜和靶向或促进锚定在脂质双层中的分子。 还提供了用于构建自组装纳米颗粒药物递送系统的方法。
-
公开(公告)号：US20120315335A1
公开(公告)日：2012-12-13
申请号：US13352637
申请日：2012-01-18
IPC分类号： A61K9/51 , A61K31/7088 , A61K38/02 , B82Y5/00
CPC分类号： A61K9/5184 , A61K9/1277 , A61K9/5192 , A61K47/6901 , A61K47/6913 , B82Y5/00 , C07K14/005 , C07K2319/00 , C12N7/00 , C12N2730/10122 , C12N2730/10123 , Y10S977/795 , Y10S977/797 , Y10S977/798 , Y10S977/80 , Y10S977/801 , Y10S977/802
摘要： A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided.
摘要翻译： 提供了用于递送药物的自组装纳米颗粒药物递送系统，包括肽，蛋白质，核酸或合成化学药物。 本文所述的自组装纳米颗粒药物递送系统包括病毒衣壳蛋白，例如包封药物的乙型肝炎病毒核心蛋白，脂质双层包膜和靶向或促进锚定在脂质双层中的分子。 还提供了用于构建自组装纳米颗粒药物递送系统的方法。
-
公开(公告)号：US20130156818A1
公开(公告)日：2013-06-20
申请号：US13609234
申请日：2012-09-10
CPC分类号： C07K14/005 , A61K9/5184 , A61K31/713 , A61K38/162 , A61K47/64 , C07K1/1072 , C07K1/1075 , C07K1/1077 , C07K1/1133 , C07K1/1136 , C12N2730/10122
摘要： Provided herein are methods and compositions for controlling assembly of modified viral core proteins, for example, into a viral capsid or a nanocage. In some embodiments, the disclosed modified viral core proteins comprise at least one mutation or modification that can substantially prevent assembly of the viral core proteins until assembly is desired. In some embodiments, assembly of the viral core proteins may be triggered, for example, by contacting the viral core proteins with a reducing agent and/or by reducing the concentration of a denaturant. The viral core proteins may self-assemble to form a viral capsid or nanocage.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.049 秒)
